Licensing agreement for novel type 3 interferonRelease and License Agreement • September 23rd, 2020 • Delaware
Contract Type FiledSeptember 23rd, 2020 JurisdictionTHIS RELEASE AND LICENSE AGREEMENT (the “Agreement”) is made and entered into as of October 22, 2008 (the “Effective Date”) by and between ZymoGenetics, Inc. having offices at 1201 Eastlake Avenue East, Seattle, WA 98102-3702 (“ZymoGenetics”), and Bristol-Myers Squibb Company, a Delaware corporation having offices at Route 206 & Province Line Road, Princeton, NJ 08543 (“BMS”).